Last reviewed · How we verify
WHO-recommended periodic presumptive treatment
WHO-recommended periodic presumptive treatment is a Antimalarial combination therapy Small molecule drug developed by University of Washington. It is currently FDA-approved for Malaria prevention in pregnant women in endemic areas, Malaria prevention in infants and children in endemic areas. Also known as: WHO PPT.
WHO-recommended periodic presumptive treatment (PPT) involves administering antimalarial drugs at regular intervals to pregnant women or other at-risk populations to prevent malaria infection regardless of parasitemia status.
WHO-recommended periodic presumptive treatment (PPT) involves administering antimalarial drugs at regular intervals to pregnant women or other at-risk populations to prevent malaria infection regardless of parasitemia status. Used for Malaria prevention in pregnant women in endemic areas, Malaria prevention in infants and children in endemic areas.
At a glance
| Generic name | WHO-recommended periodic presumptive treatment |
|---|---|
| Also known as | WHO PPT |
| Sponsor | University of Washington |
| Drug class | Antimalarial combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | FDA-approved |
Mechanism of action
PPT is a preventive strategy that delivers therapeutic doses of antimalarials (typically sulfadoxine-pyrimethamine or artemisinin-based combinations) on a fixed schedule rather than waiting for confirmed infection. This approach reduces the burden of malaria parasites in the blood and tissues, preventing clinical disease and complications such as severe anemia and low birth weight in pregnant women. The strategy is particularly effective in areas of moderate to high malaria transmission.
Approved indications
- Malaria prevention in pregnant women in endemic areas
- Malaria prevention in infants and children in endemic areas
Common side effects
- Gastrointestinal disturbance
- Rash
- Hypersensitivity reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WHO-recommended periodic presumptive treatment CI brief — competitive landscape report
- WHO-recommended periodic presumptive treatment updates RSS · CI watch RSS
- University of Washington portfolio CI
Frequently asked questions about WHO-recommended periodic presumptive treatment
What is WHO-recommended periodic presumptive treatment?
How does WHO-recommended periodic presumptive treatment work?
What is WHO-recommended periodic presumptive treatment used for?
Who makes WHO-recommended periodic presumptive treatment?
Is WHO-recommended periodic presumptive treatment also known as anything else?
What drug class is WHO-recommended periodic presumptive treatment in?
What development phase is WHO-recommended periodic presumptive treatment in?
What are the side effects of WHO-recommended periodic presumptive treatment?
Related
- Drug class: All Antimalarial combination therapy drugs
- Manufacturer: University of Washington — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Parasitology
- Indication: Drugs for Malaria prevention in pregnant women in endemic areas
- Indication: Drugs for Malaria prevention in infants and children in endemic areas
- Also known as: WHO PPT
- Compare: WHO-recommended periodic presumptive treatment vs similar drugs
- Pricing: WHO-recommended periodic presumptive treatment cost, discount & access